Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
#YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=120657

Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.
#YonhapInfomax #Celltrion #Eyedenzelt #PatentSettlement #GlobalMarket #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99424

💊💉 #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 10. Date of revision of the text on 20 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history

💊💉 #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 2. Qualitative and quantitative composition; 4.6 Fertility, pregnancy and lactation; 5.2 Pharmacokinetic properties; 6.5 Nature and contents of container; 10. Date of revision of the text on 01 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history